Docetaxel for the treatment of hormone-refractory metastatic prostate cancer

  • Technology appraisal guidance
  • TA101
  • Published: 
Download guidance (PDF)

Update information

March 2014: Implementation section updated to clarify that docetaxel is recommended as an option for treating hormone-refractory metastatic prostate cancer.

ISBN: 978-1-4731-7020-9